Q-omics provides the consensus-scored SMIM28 profile across patient tissues and cancer cell-line models. SMIM28 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SMIM28 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SMIM28 RNA expression shows 7,403 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where SMIM28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM28 survival associations across molecular data types. SMIM28 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM28 RNA expression–survival associations across cancer types. High SMIM28 expression shows unfavorable associations in KIRC, BRCA, LUAD, ACC and UVM, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SMIM28 RNA expression.
This table summarizes SMIM28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM28 shows lower tumor expression in COAD, KIRC, READ, KICH and THCA and higher tumor expression in PRAD. The COAD box plot shows higher SMIM28 RNA expression in normal versus tumor tissue (log2 FC = −1.001, t-test p < 0.001).
This table shows molecular features associated with SMIM28 in patient tissues and cancer cell lines. In patient samples, SMIM28 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
